Reviewer's report

**Title:** NKTR-102 versus irinotecan as an approach for the treatment of brain metastasis of breast cancer

**Version:** 2  **Date:** 20 May 2015

**Reviewer:** Aleix Prat

**Reviewer's report:**

This is a very nice paper, very well written and explained. The topic has its importance since brain metastases are a major issue in the clinic and, to date, no effective drugs exists. The authors show very nicely in a single preclinical model that a PEGylated irinotecan conjugate is more effective than conventional irinotecan.

I have no major or minor revisions.

As discretionary revisions, and in other to further improve the paper, I would suggest to show the same experiments in a second breast cancer preclinical model, probably a luminal or a HER2+ model. However, I realize this is a huge amount of work and the current article is very complete.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

'I declare that I have no competing interests